Neurocrine wants to develop new obesity drugs. It’s making an acquisition to accelerate that move.

Neurocrine's potential acquisition of Soleno Therapeutics is driving a surge in Soleno's stock price, with significant implications for the biotech sector. This deal could accelerate Neurocrine's entry into the obesity drug market, impacting related stocks and the broader healthcare industry. The acquisition news is expected to have a short-term impact on Soleno's stock and potentially influence the valuation of similar biotech companies.